Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus.
(2011) In Rheumatology (Oxford, England) 50. p.1064-1069- Abstract
- Objectives. SLE is a systemic autoimmune disease with an annual incidence of 3.8 per 100 000. Several pathogenic mechanisms are believed to be operating in SLE, including an impaired clearance of apoptotic cells, activation of the type I IFN pathway and generation of autoimmune leucocytes. Growth arrest-specific protein 6 (Gas6) and its receptor Axl are known to regulate inflammation and may be implicated in lupus pathogenesis. We have recently developed immunological methods to quantify the vitamin-K-dependent protein Gas6 and its soluble receptor sAxl in human plasma, which we have used to investigate the role of Gas6 and soluble Axl in SLE. Methods. We have investigated the relation between the plasma concentrations of Gas6 and sAxl and... (More)
- Objectives. SLE is a systemic autoimmune disease with an annual incidence of 3.8 per 100 000. Several pathogenic mechanisms are believed to be operating in SLE, including an impaired clearance of apoptotic cells, activation of the type I IFN pathway and generation of autoimmune leucocytes. Growth arrest-specific protein 6 (Gas6) and its receptor Axl are known to regulate inflammation and may be implicated in lupus pathogenesis. We have recently developed immunological methods to quantify the vitamin-K-dependent protein Gas6 and its soluble receptor sAxl in human plasma, which we have used to investigate the role of Gas6 and soluble Axl in SLE. Methods. We have investigated the relation between the plasma concentrations of Gas6 and sAxl and disease activity and specific symptoms in 96 SLE patients. Results. Gas6 and sAxl concentrations correlated with SLEDAI (r = 0.48, P < 0.001 and r = 0.39, P < 0.001, respectively). Furthermore, concentrations of Gas6 and sAxl correlated with ESR and CRP and inversely with haemoglobin levels. Gas6 and sAxl concentrations were significantly higher in patients with anti-DNA antibodies, leucopenia and GN. Conclusion. The plasma concentrations of Gas6 and sAxl vary with disease activity in SLE, in particular GN, and may have a role in lupus pathogenesis. Furthermore, Gas6 and sAxl may be of use as biomarkers of disease activity. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1832571
- author
- Ekman, Carl LU ; Jönsen, Andreas LU ; Sturfelt, Gunnar LU ; Bengtsson, Anders LU and Dahlbäck, Björn LU
- organization
- publishing date
- 2011
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Rheumatology (Oxford, England)
- volume
- 50
- pages
- 1064 - 1069
- publisher
- Oxford University Press
- external identifiers
-
- wos:000290589600010
- pmid:21278074
- scopus:85012054549
- ISSN
- 1462-0332
- DOI
- 10.1093/rheumatology/keq459
- language
- English
- LU publication?
- yes
- id
- 42c9b714-fa7d-4892-a106-2205c3f616a8 (old id 1832571)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/21278074?dopt=Abstract
- date added to LUP
- 2016-04-04 09:07:28
- date last changed
- 2022-05-01 08:00:58
@article{42c9b714-fa7d-4892-a106-2205c3f616a8, abstract = {{Objectives. SLE is a systemic autoimmune disease with an annual incidence of 3.8 per 100 000. Several pathogenic mechanisms are believed to be operating in SLE, including an impaired clearance of apoptotic cells, activation of the type I IFN pathway and generation of autoimmune leucocytes. Growth arrest-specific protein 6 (Gas6) and its receptor Axl are known to regulate inflammation and may be implicated in lupus pathogenesis. We have recently developed immunological methods to quantify the vitamin-K-dependent protein Gas6 and its soluble receptor sAxl in human plasma, which we have used to investigate the role of Gas6 and soluble Axl in SLE. Methods. We have investigated the relation between the plasma concentrations of Gas6 and sAxl and disease activity and specific symptoms in 96 SLE patients. Results. Gas6 and sAxl concentrations correlated with SLEDAI (r = 0.48, P < 0.001 and r = 0.39, P < 0.001, respectively). Furthermore, concentrations of Gas6 and sAxl correlated with ESR and CRP and inversely with haemoglobin levels. Gas6 and sAxl concentrations were significantly higher in patients with anti-DNA antibodies, leucopenia and GN. Conclusion. The plasma concentrations of Gas6 and sAxl vary with disease activity in SLE, in particular GN, and may have a role in lupus pathogenesis. Furthermore, Gas6 and sAxl may be of use as biomarkers of disease activity.}}, author = {{Ekman, Carl and Jönsen, Andreas and Sturfelt, Gunnar and Bengtsson, Anders and Dahlbäck, Björn}}, issn = {{1462-0332}}, language = {{eng}}, pages = {{1064--1069}}, publisher = {{Oxford University Press}}, series = {{Rheumatology (Oxford, England)}}, title = {{Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus.}}, url = {{http://dx.doi.org/10.1093/rheumatology/keq459}}, doi = {{10.1093/rheumatology/keq459}}, volume = {{50}}, year = {{2011}}, }